Genevant enters partnership with Takeda for developing rare liver disease therapies

September 08, 2021 | News Commentary

Genevant Sciences develops lipid nanoparticle (LNP) nucleic acid delivery techniques, which can be utilized for mRNA-based applications including vaccines, protein production, and nonviral gene therapies. The two companies reached an...